CoChat

IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia

Open access
Scheffold, Annika, Jebaraj, Billy Michael Chelliah, Tausch, Eugen, Bloehdorn, Johannes, Ghia, Paolo, Yahiaoui, Anella, Dolnik, Anna, Blätte, Tamara Jacqueline, Bullinger, Lars, Dheenadayalan, Rashmi Priyadharshini, Li, Li, Schneider, Christof, Chen, Shih-Shih, Chiorazzi, Nicholas, Dietrich, Sascha, Seiffert, Martina, Tannheimer, Stacey, Döhner, Hartmut, Mertens, Daniel, Stilgenbauer, Stephan · 2019 · Blood
Cited by 55

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Targeted therapy is revolutionizing the treatment of cancers, but resistance evolves against these therapies and derogates their success. The phosphatidylinositol 3-kinase delta (PI3K-δ) inhibitor idelalisib has been approved for treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma, but the mechanisms conferring resistance in a subset of patients are unknown. Here, we modeled resistance to PI3K-δ inhibitor in vivo using a serial tumor transfer and treatment scheme in mice. Whole-exome sequencing did not identify any recurrent mutation explaining resistance to PI3K-δ inhibitor. In the murine model, resistance to PI3K-δ inhibitor occurred as a result of a signaling switch mediated by consistent and functionally relevant activation of insulin-like growth factor 1 receptor (IGF1R), resulting in enhanced MAPK signaling in the resistant tumors. Overexpression of IGF1R in vitro demonstrated its prominent role in PI3K-δ inhibitor resistance. IGF1R upregulation in PI3K-δ inhibitor–resistant tumors was mediated by functional activation and enhanced nuclear localization of forkhead box protein O1 transcription factors and glycogen synthase kinase 3β. In human CLL, high IGF1R expression was associated with trisomy 12. CLL cells from an idelalisib-treated patient showed decreased sensitivity to idelalisib in vitro concomitant with enhanced MAPK signaling and strong upregulation of IGF1R upon idelalisib exposure. Thus, our results highlight that alternative signaling cascades play a predominant role in the resistance and survival of cancer cells under PI3K-δ inhibition. We also demonstrate that these pathway alterations can serve as therapeutic targets, because inhibition of IGF1R offered efficacious salvage treatment of PI3K-δ inhibitor–resistant tumors in vitro and in vivo.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2018881029

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 55

Metadata

Authors
Scheffold, A., Jebaraj, B. M. C., Tausch, E., Bloehdorn, J., Ghia, P., Yahiaoui, A., Dolnik, A., Blätte, T. J., Bullinger, L., Dheenadayalan, R. P., Li, L., Schneider, C., Chen, S.-S., Chiorazzi, N., Dietrich, S., Seiffert, M., Tannheimer, S., Döhner, H., Mertens, D., & Stilgenbauer, S.
Venue
Blood
Published
2019-08-08
Volume
134
Issue
6
Pages
534-547
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2941778812
Cited by
55
References
7
FWCI
3.82
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia. https://app.cochat.ai/papers/10.1182/blood.2018881029
The paper
Scheffold, A., Jebaraj, B. M. C., Tausch, E., Bloehdorn, J., Ghia, P., Yahiaoui, A., Dolnik, A., Blätte, T. J., Bullinger, L., Dheenadayalan, R. P., Li, L., Schneider, C., Chen, S.-S., Chiorazzi, N., Dietrich, S., Seiffert, M., Tannheimer, S., Döhner, H., Mertens, D., & Stilgenbauer, S. (2019). IGF1R as druggable target mediating PI3K-δ inhibitor resistance in a murine model of chronic lymphocytic leukemia. Blood. https://doi.org/10.1182/blood.2018881029

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.